Roche (PINK:RHHBY) this week warned of potential issues with its Accu-Check Connect diabetes management application which could lead the app to provide inaccurate bolus insulin recommendations.
The Swiss company said it recently discovered a software bug in its Accu-Check Connect diabetes management app versions 2.0.0, 2.0.1 and 2.1.0 for Apple (NSDQ:AAPL) iOS and Google (NSDQ:GOOG) Android devices which may cause the bolus advisor to display an incorrect active insulin amount of 0.
